The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis ABSTRACT The field of spondyloarthritis (SpA) has experienced major progress in the last decade, especially with regard to new treatments, earlier diagnosis, imaging technology and a better definition of outcome parameters for clinical trials. In the present work, the Assessment in SpondyloArthritis international Society (ASAS) provides a comprehensive handbook on the most relevant aspects for the assessments of spondyloarthritis, covering classification criteria, MRI and x rays for sacroiliac joints and the spine, a complete set of all measurements relevant for clinical trials and international recommendations for the management of SpA. The handbook focuses at this time on axial SpA, with ankylosing spondylitis (AS) being the prototype disease, for which recent progress has been faster than in peripheral SpA. The target audience includes rheumatologists, trial methodologists and any doctor and/or medical student interested in SpA. The focus of this handbook is on practicality, with many examples of MRI and x ray images, which will help to standardise not only patient care but also the design of clinical studies.
The field of spondyloarthritis (SpA) has faced tremendous changes over the last decade. Undoubtedly, these changes were triggered by the development of several effective therapies for ankylosing spondylitis (AS). Drug development and registration nowadays requires appropriate classification criteria to sharply delineate the trial population of interest as well as a validated toolset for measuring outcome of clinical trials.
The Assessment of SpondyloArthritis international Society (ASAS) (formerly ASsessment in Ankylosing Spondylitis), was initiated in 1995 to bring evidence-based unity in the multitude of assessments in the field of AS, has broadened its scope to the entire spectrum of SpA later on, and has extended its work to measuring treatment response in clinical trials, the re-evaluation of existing classification criteria and the development of diagnostic criteria for SpA. This all to achieve the mission of ASAS, which is the support and promotion of translational and clinical research of spondyloarthritis. The ultimate goal is to improve the well-being and outcome of patients with spondyloarthritis. The means to achieve this goal include: (1) increasing awareness of spondyloarthritis, (2) facilitating early diagnosis, (3) developing and validating assessment tools and (4) evaluating treatment modalities. ASAS, which is a worldwide forum consisting of clinical rheumatologists, methodologists, workers in pharmaceutical industry and others, has always collaborated with organisations such as the Outcome Measures In Rheumatology Clinical Trials (OMERACT) group and the European League Against Rheumatism (EULAR).
One of the first ASAS efforts was the delineation of relevant domains of outcome in AS and the development of a core set of outcome measures to be used in clinical trials (for physiotherapy and diseasemodifying antirheumatic drugs (DMARDs)) and in clinical practice (core set for clinical record keeping). Since then, the core set has been updated regularly and there has not been a single field in outcome assessment that ASAS has not addressed. Important achievements with relevant implications have been the development of response criteria for clinical trials (ASAS20, ASAS40, ASAS 5/6 and ASAS partial remission), the validation of measurement instruments for radiographic damage and progression and for magnetic resonance inflammation, and recently the development of a new index for measuring disease activity, the Ankylosing Spondylitis Disease Activity Score (ASDAS).
Since 1995, ASAS-endorsed assessments and response measures have been applied in several clinical trials in AS and SpA and have proven to be extremely valuable in the evaluation of pharmaceutical and non-pharmaceutical treatments and in drug registration.
The ASAS handbook in front of you reads like a compendium of ASAS history. It provides a complete picture of all measurements that have been investigated and developed during the last 13 years, including the ASAS core set. It provides insight in available and newly developed criteria for classifying SpA and it exemplifies response criteria as well as recent achievements in measuring disease activity. Moreover, there is extensive focus on abnormalities seen on imaging (mainly radiographs and MRI) in sacroiliac (SI) joints and spine; features characteristic for SpA, but also caveats that can easily be misinterpreted. New definitions on how to define a positive MRI are also provided.
The handbook focuses on axial SpA, since the development of outcome assessment started in AS, the prototype disease in the spectrum of SpA. Peripheral SpA is not ignored at all, but the picture for this disease is not yet complete and the handbook will be updated once new developments in this field have been substantiated.
The target audience for the ASAS handbook includes every rheumatologist who is interested in measuring and monitoring patients with SpA in clinical practice as well as clinical researchers in the field of SpA, since it gives detailed descriptions of how tests should be performed. Trial methodologists and other workers in the pharmaceutical industry assigned to the development and conduct of clinical trials will find which outcome measures to choose in trials, how to describe them in the protocol and how to practically teach and use them in the trial. Workers in the regulatory field may use the handbook as a guide to judge the trial performance and robustness. And medical students will find a quick overview of what is important in the field of outcomes in SpA.
Although the handbook aims to be comprehensive in terms of content, the focus is on practicality rather than on understanding background and performance. The reader of the handbook will, for example, find how to perform the modified Schober test or how to score radiographs according to the modified Stoke Ankylosing Spondylitis Spine Score (SASSS), but will not be informed about the relative performance of this test or method in comparison with others. More information on this can be found in the reference list.
The ASAS handbook is published by-and under the responsibility of-the ASAS executive committee, and will be regularly updated.
PART A: CLASSIFICATION CRITERIA
In this section all recent classification criteria for spondyloarthritis are listed, starting with the 1984 modified New York criteria for ankylosing spondylitis, followed by the 1990/1991 Amor criteria and the European Spondyloarthropathy Study Group (ESSG) criteria for spondyloarthritis, which cover the whole spectrum of SpA including axial and peripheral SpA and also the early phase of the disease without chronic x ray changes. The most recent ASAS classification criteria for axial spondyloarthritis were developed for early and established cases and include the MRI technique (active inflammation) as an important tool for early diagnosis. ASAS criteria for peripheral SpA are pending and are currently being developed. For diagnosis in daily clinical practice, a more flexible approach is often necessary than is offered by classification criteria that ask for a clear ''yes'' or ''no'' response. A diagnostic algorithm for axial SpA based on calculation of likelihood ratios for the clinical, laboratory and imaging parameters typical for SpA has been proposed recently, 1 2 but was not discussed by ASAS and therefore not included in this handbook. The listed criteria for inflammatory back pain (IBP) have a similar performance and can all be used in daily clinical practice. For the development of the ASAS criteria for axial SpA the ASAS-expert IBP criteria were used.
Box 2 Amor criteria for spondyloarthritis 4
A patient is considered to have spondyloarthritis if the sum of the point counts is 6 or more. A total point count of five or more classifies for probable spondyloarthritis. 
PART B: MRI
MRI studies of the sacroiliac joints and the spine in patients with SpA have made a major contribution in the last decade to a better understanding of the course of the disease, to an early diagnosis and have been used as an objective outcome measure for clinical trials. Active inflammatory changes are visualised best by fatsaturated T2-weighted turbo spin-echo sequence or a short tau inversion recovery (STIR) sequence with a high resolution (image matrix of 512 pixels, slice thickness of 3 mm or 4 mm), which can detect even minor fluid collections such as bone marrow oedema. Alternatively, administration of a paramagnetic contrast medium (gadolinium) detects increased perfusion (osteitis) in a T1-weighted sequence with fat saturation. These two sequences give largely overlapping information, although occasionally applying both methods can give additional value. Chronic changes such as fatty degeneration and erosions are best seen by using a T1-weighted turbo spin-echo sequence.
MRI of the axial skeleton is performed with whole-body scanners with a field strength of 1.0 or 1.5 Tesla, preferably using special spinal or body phased-array coils. The SI joints are imaged using a semicoronal section orientation along the long axis of the sacral bone. The protocol comprises a T1-weighted turbo spin-echo sequence, a T2-weighted gradient-echo sequence using the opposed-phase technique and a STIR sequence with slices of 4 mm thickness. The whole sacral bone should be covered from its anterior to its posterior border, which usually requires at least 10-12 slices. Administration of a paramagnetic contrast medium (gadolinium), usually followed by imaging with a fat-saturated T1-weighted turbo spin-echo sequence, might give additional information on active inflammation.
An efficient spinal imaging protocol comprises a sagittal T1-weighted turbo spin-echo sequence and a sagittal fat-saturated T2-weighted turbo spin-echo sequence, or STIR sequence with a high resolution. If a paramagnetic contrast medium is administered, a T1-weighted sequence with fat saturation should be used in a sagittal orientation. Transverse slices are useful for assessment of the posterior parts of the spine. However, for routine imaging of the spine transverse sequences are time consuming and therefore less feasible. Coronal slices of the entire spine may be used for better assessment of the costovertebral and costotransverse joints and of the facet joints.
In the following section, a detailed description of active inflammatory and chronic lesions of the sacroiliac joints and the spine typical for SpA is given, with many examples of images. Because active inflammation of the SI joints has become an important parameter for early diagnosis of axial SpA, special emphasis has been given to define a ''positive lesion''. Furthermore, pitfalls in the diagnosis of SpA-specific MRI findings are discussed and shown.
Before assessing the active inflammatory or chronic lesions on MRI it is necessary to define the MRI sequence of the image in question. This can normally be done by looking at spinal fluid, intervertebral discs and subcutaneous fat tissue (see Box 8) .
Several scoring methods for assessing inflammatory activity in the spine and sacroiliac joints have been used in the past and have also recently been compared with each other. 10 11 However, none of them has been proven so far to be superior. Therefore, these scores have not been included in this handbook at this time point but may be added later on. 
Box 10 Active inflammatory lesions: bone marrow oedema (osteitis)
c Hyperintense signal on STIR images (bone marrow oedema) and/or on contrast-enhanced T1-weighted fat-saturated images (osteitis). The stronger the hyperintense signal the more likely it reflects active inflammation (intensity of the hyperintense signal is similar to that of blood vessels or spinal fluid). c Bone marrow oedema (BME) is an indicator of active sacroiliitis but may be found in other pathologies as well. c Affected bone marrow areas are located periarticularly. c BME may be associated with structural changes such as erosions.
A-E. Bone marrow oedema/osteitis: affected bone marrow areas (arrows) are located periarticularly (short tau inversion recovery (STIR)). F. Bone marrow oedema/ osteitis: bone marrow oedema may be associated with structural changes such as erosions (arrow) (STIR). B and D have been reproduced from Rudwaleit. c Synovitis is reflected by hyperintense signals on contrastenhanced T1-weighted fat-saturated images in the synovial part of the SI joints (similar to blood vessels). STIR sequences do not differentiate between synovitis and joint fluid. c Synovitis on MRI as a single feature (without BME) is a rare finding and may not suffice for making an imaging diagnosis of sacroiliitis.
Synovitis (arrows) of both sacroiliac joints (contrast-enhanced T1-weighted fat-saturated images). This figure has been reproduced from Rudwaleit.
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Box 12 Active inflammatory lesions: capsulitis c Capsulitis is comparable to synovitis in terms of signal characteristics but these changes involve the anterior and posterior capsule. Anteriorly, the joint capsule gradually continues into the periosteum of the iliac and sacral bones and thus corresponds to an enthesis. Capsulitis, therefore, may extend far medially and laterally into the periosteum. Capsulitis may be better detectable using contrast-enhanced T1-weighted fat-saturated images as compared to STIR.
Capsulitis (arrows) (contrast-enhanced T1-weighted fat-saturated images). Osteitis of the right sacroiliac joint (active sacroiliitis) can also be seen in this patient. This figure has been reproduced from Rudwaleit.
Box 13 Active inflammatory lesions: enthesitis
c Hyperintense signal on STIR images and/or on contrast-enhanced T1-weighted fat-saturated images at sites where ligaments and tendons attach to bone, including the retroarticular space (interosseous ligaments). The signal may extend to bone marrow and soft tissue. Enthesitis may be better detectable using contrast-enhanced T1-weighted fat-saturated images as compared to STIR.
A. 1: Enthesitis (white arrow) of interosseous ligaments (contrast-enhanced T1-weighted fat-saturated images; coronal view). Also present: osteitis of the left iliac bone (black arrow). 2: Enthesitis (white arrows) of interosseous ligaments (contrast-enhanced T1-weighted fat-saturated images; axial view). Also present: osteitis of the left sacroiliac joint (black arrow). B. Box 21 Definition of sacroiliitis highly suggestive of SpA (''positive MRI'') for application in the new ASAS classification criteria 6 (Reproduced from Rudwaleit.
)
A. Types of findings required for definition of sacroiliitis by MRI c Active inflammatory lesions of the SI joints (reflecting active sacroiliitis) are required for the definition of ''sacroiliitis on MRI'' as one of the two imaging items in the ASAS classification criteria for axial SpA. c BME (STIR) or osteitis (T1 post-gadolinium) highly suggestive of SpA must be clearly present and located in the typical anatomical areas (subchondral or periarticular bone marrow). c The sole presence of other active inflammatory lesions such as synovitis, enthesitis or capsulitis without concomitant BME/osteitis is not sufficient for the definition of sacroiliitis on MRI. c Structural lesions such as fat deposition, sclerosis, erosions or bony ankylosis are likely to reflect previous inflammation. At this time, however, the consensus group felt that the sole presence of structural lesions without concomitant BME/osteitis does not suffice for the fulfilment of sacroiliitis on MRI in the ASAS classification criteria for axial SpA. B. Amount of signal required c If there is only one signal (lesion) per MRI slice suggesting active inflammation, the lesion should be present on at least two consecutive slices. If there is more than one signal (lesion) on a single slice, one slice may be sufficient. 
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Figure 12
Bone marrow oedema of a whole vertebral body and adjacent vertebrae (short tau inversion recovery (STIR)). 
PART C: X RAYS
x Rays of sacroiliac joints and spine have been used since the 1930s for diagnosis and staging of patients with AS. In contrast to MRI, x rays can only detect chronic bony changes (damage), which are the consequence of inflammation and not inflammation itself. Therefore, x rays are not suitable for early diagnosis of spondyloarthritis but are still the method of choice for the detection of chronic changes, and as such are widely used for diagnostic purposes in patients with already established disease (modified New York criteria for SI joints). Chronic changes of the spine, especially syndesmophytes, are not part of current classification or diagnostic criteria for AS because the disease nearly always starts in the SI joints, and the presence of spinal syndesmophytes with radiologically normal SI joints is a rare, although possible, event. While early destructive changes such as erosions can also be seen by x rays, this method is mostly superior to MRI for the detection of new bone formation such as ankylosis and syndesmophytes. Different approaches have been proposed for the radiological investigation of the SI joints with the intention to get an optimal view of this irregularly-shaped joint. None of them have been shown to be clearly superior. ASAS recommends performing x rays of the whole pelvis because this allows the assessment of the hip joints as well as the SI joints, which are relatively frequently affected in spondyloarthritis. In order to show a clearer view of the SI joints, in most of the images in this handbook the hip joints are not shown. Regarding the spine, x rays of the cervical and lumbar spine should be performed. Although changes in the thoracic spine are frequent, they are more difficult to detect because of the overlying lung tissue and therefore radiographs of the thoracic spine are not routinely assessed. The preferred method for scoring chronic changes of the spine in clinical studies, the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), investigates only lateral views of the cervical and lumbar spine.
Other imaging techniques
Scintigraphy has been used for many decades for the detection for active inflammation in patients with SpA, but no longer plays a role in diagnosis and management of patients with SpA because of limited sensitivity and specificity 13 and has been replaced by MRI. Chronic bony changes can be better detected by computed tomography (CT) in comparison to x rays. However, CT is rarely used because of a much higher radiation exposure. It can be helpful in the differential diagnosis of diffuse idiopathic skeletal hyperostosis (DISH, or Forestier disease; see fig 40) . Active inflammatory changes can also not be seen by CT, and fatty degeneration of the bone marrow (as an early sign of chronic changes) is only detectable by MRI and not by CT. It has to be seen in the future whether MRI, as another tomography technique, can replace CT in the assessment of chronic bony changes. Therefore, images of scintigraphy and CT (only exception: fig 40) have not been included in this handbook. 
X RAYS OF THE SACROILIAC JOINTS IN PATIENTS WITH SPONDYLOARTHRITIS

X RAYS OF THE SPINE IN PATIENTS WITH SPONDYLOARTHRITIS
Vertebral bodies Figure 42 The two panels of the lateral lumbar spine were taken with a 2-year interval. At baseline indicated with a large arrow there is a very small and thin syndesmophyte at the upper corner of lumbar 2. By 2 years later this has evolved to a bridging syndesmophyte. At the sites indicated by the smaller arrows there are already bridging syndesmophytes at baseline but they showed progression over a 2-year period. 
PART D: CLINICAL ASSESSMENT/OUTCOME MEASUREMENTS
In the following section the ASAS-endorsed outcome measures will be described in detail. It will start with a description of the different core sets (most recently updated version) and it will provide detailed information about the different measurement instruments. The focus is on practicality, and if necessary illustrative pictures have been added to further clarify. Assessments will be addressed domain-wise, which means that measures of disease activity will be discussed separately from measures of spinal mobility, or scoring methods for radiographic progression.
There is also a detailed overview of validated ASAS-endorsed response criteria and how to use them in clinical trials, and the newly developed ASDAS formulae will be presented.
Box 24 ASAS/OMERACT core domains for ankylosing spondylitis 17 Table 4 Assessment of SpondyloArthritis international Society (ASAS) core set for disease-controlling antirheumatic treatments (DC-ART) 17 
Domain
Instrument 19 (Adapted with permission from J Rheumatol.)
Items to be scored by the patient:
c Putting on your socks or tights without help or aids (eg, sock aid).
c Bending forward from the waist to pick up a pen from the floor without an aid.
c Reaching up to a high shelf without help or aids (eg, helping hand).
c Getting up out of an armless dining room chair without using your hands or any other help.
c Getting up off the floor without help from lying on your back.
c Standing unsupported for 10 min without discomfort.
c Climbing 12 to 15 steps without using a handrail or walking aid. One foot at each step.
c Looking over your shoulder without turning your body.
c Doing physically demanding activities (eg, physiotherapy, exercises, gardening or sports).
c Doing a full day's activities, whether it be at home or at work.
The BASFI is the mean of 10 item scores completed on a numerical rating scale.
Alternatively, a VAS between 0 and 100 can be used. ASAS prefers to use an NRS. .70u
The sum of the five assessments gives the BASMI 3 result. Reproduced with permission from J Rheumatol. Optimal management of AS requires a combination of non-pharmacological and pharmacological treatments 4
Non-pharmacological treatment of AS should include patient education and regular exercise. Individual and group physical therapy should be considered. Patient associations and self-help groups may be useful. 5
NSAIDs are recommended as first line drug treatment for patients with AS with pain and stiffness. In those with increased GI risk, non-selective NSAIDs plus a gastroprotective agent, or a selective COX-2 inhibitor could be used. 6 Analgesics, such as paracetamol and opioids, might be considered for pain control in patients in whom NSAIDs are insufficient, contraindicated and/or poorly tolerated. 7
Corticosteroid injections directed to the local site of musculoskeletal inflammation may be considered. The use of systemic corticosteroids for axial disease is not supported by evidence. 8
There is no evidence for the efficacy of DMARDs, including sulfasalazine and methotrexate, for the treatment of axial disease. Sulfasalazine may be considered in patients with peripheral arthritis. 9
Anti-TNF treatment should be given to patients with persistently high disease activity despite conventional treatments according to the ASAS recommendations. There is no evidence to support the obligatory use of DMARDs before, or concomitant with, anti-TNF treatment in patients with axial disease. 10 Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic evidence of structural damage, independent of age. Spinal surgery, for example, corrective osteotomy and stabilisation procedures, may be of value in selected patients.
COX-2, cyclo-oxygenase 2; DMARDs, disease-modifying antirheumatic drugs; GI, gastrointestinal; NSAIDs, non-steroidal antiinflammatory drugs; TNF, tumour necrosis factor. Basal cell carcinoma Malignancies diagnosed and treated more than 10 years previously (where the probability of total cure is very high) Assessment of disease: ASAS core set for daily practice Physical function (BASFI) Pain (NRS/VAS, past week, spine at night, from ankylosing spondylitis and NRS/VAS, past week, spine, from ankylosing spondylitis) Spinal mobility (chest expansion, modified Schober, occiput to wall distance and lateral lumbar flexion) Patient global assessment (NRS/VAS, past week) Stiffness (duration of morning stiffness, spine, past week) Peripheral joints and entheses (number of swollen joints (44 joints count), enthesitis score such as MASES, Berlin, or San Francisco) Acute phase reactants (ESR or CRP) Fatigue (NRS/VAS) BASDAI NRS/VAS overall level of fatigue/tiredness, past week NRS/VAS overall level of ankylosing spondylitis neck, back or hip pain, past week NRS/VAS overall level of pain/swelling in joints other than neck, back or hips, past week NRS/VAS overall discomfort from any areas tender to touch or pressure, past week VAS overall level of morning stiffness from time of awakening, past week Duration and intensity (VAS) of morning stiffness from time of awakening (up to 120 min) Assessment of response: Responder criteria BASDAI: 50% relative change or absolute change of 20 mm (on a scale between 0 and 100) and expert opinion in favour of continuation Time of evaluation Between 6 and 12 weeks *The expert is a doctor, usually a rheumatologist, with expertise in ankylosing spondylitis and the use of biological agents (expert should be locally defined); {the expert should consider clinical features (history and examination), serum acute phase reactant levels and/or imaging results, such as radiographs demonstrating rapid progression or MRI indicating ongoing inflammation; {sulfasalazine: treatment for at least 4 months at standard target dose or maximally tolerated dose unless contraindicated or not tolerated. Treatment for less than 4 months, where treatment was withdrawn because of intolerance or toxicity or contraindicated. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesis Score; NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale (all VAS can be replaced by a numerical rating scale (NRS)).
